Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging study hopes to see inside scarred livers

NCT ID NCT07069725

First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 26 times

Summary

This early-stage study tests a single dose of an experimental drug (AZD2389) in 12 adults with advanced liver scarring (cirrhosis). The main goal is to see how well the drug attaches to its target in the liver using a special PET scan. This is not a treatment study; it is designed to measure how the drug works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    WITHDRAWN

    Solna, 171 64, Sweden

  • Research Site

    RECRUITING

    Stockholm, 17176, Sweden

Conditions

Explore the condition pages connected to this study.